News

Genentech Presents Positive Data from Trials on Crenezumab and Gantenerumab for Alzheimer’s

The latest clinical data from Genentech on crenezumab and gantenerumab demonstrate the investigational therapies’ potential to reduce amyloid aggregates in Alzheimer’s disease patients. Trial results were discussed in several presentations at the 2018 Alzheimer’s Association International Conference (AAIC), recently held in Chicago. “The range of data that…

Aggressive Efforts to Lower Blood Pressure Also Drops Risk of Cognitive Impairment and Dementia, Trial Shows

Intensive efforts to lower blood pressure — dropping systolic blood pressure, particularly, to lower-than-recommended levels — can reduce a person’s risk of the mild cognitive impairment that may precede Alzheimer’s and of dementia, results of clinical trial show. “This is the first randomized clinical trial to demonstrate a reduction in…